Scarlet fever is a toxin-mediated clinical syndrome caused by Streptococcus pyogenes infection, usually presenting in children with fever, pharyngitis, a diffuse erythematous rash, and oral findings such as strawberry tongue.
Ask a research question about Scarlet Fever. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Scarlet Fever
creation_date: '2026-05-06T22:21:23Z'
updated_date: '2026-05-06T22:21:23Z'
description: >-
Scarlet fever is a toxin-mediated clinical syndrome caused by Streptococcus
pyogenes infection, usually presenting in children with fever, pharyngitis,
a diffuse erythematous rash, and oral findings such as strawberry tongue.
category: Infectious
disease_term:
preferred_term: scarlet fever
term:
id: MONDO:0005952
label: scarlet fever
parents:
- Bacterial infection
infectious_agent:
- name: Streptococcus pyogenes
infectious_agent_term:
preferred_term: Streptococcus pyogenes
term:
id: NCBITaxon:1314
label: Streptococcus pyogenes
description: >-
Group A Streptococcus that can cause pharyngitis and toxin-mediated scarlet
fever.
evidence:
- reference: PMID:37062653
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Scarlet fever is caused by a pyrogenic exotoxin-producing
streptococcus-Streptococcus pyogenes-responsible for more than 500,000
deaths annually worldwide.
explanation: This review directly identifies Streptococcus pyogenes as the infectious cause of scarlet fever.
transmission:
- name: Antimicrobial treatment reduces transmission
description: >-
Early diagnosis and antimicrobial treatment reduce onward transmission of
group A streptococcal pharyngitis associated with scarlet fever.
evidence:
- reference: PMID:37493159
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Early diagnosis and antimicrobial treatment are recommended to prevent
suppurative complications (e.g., cervical lymphadenitis, peritonsillar
abscess) and non-suppurative complications (particularly rheumatic fever)
as well as to reduce the severity of symptoms, to shorten the duration
of the illness and to reduce disease transmission.
explanation: This supports respiratory-transmissible GAS pharyngitis control through antimicrobial treatment that reduces disease transmission.
prevalence:
- population: Children in Chongqing, China
percentage: Highest incidence in ages 3-7 during 2005-2023 surveillance
evidence:
- reference: PMID:39350134
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Children aged 3-7 were the primary victims of this disease, with the
highest average incidence found among children aged 6 (5.0002 per 100,000
people).
explanation: This surveillance study supports pediatric predominance and the highest age-specific burden in young children.
- population: Shanghai, China
percentage: 25,539 notifiable cases from 2011 to 2024
evidence:
- reference: PMID:40487265
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
From 2011 to 2024, a total of 25,539 cases of scarlet fever were reported
in Shanghai.
explanation: This population surveillance study quantifies a regional scarlet fever burden.
pathophysiology:
- name: Streptococcal pharyngeal infection
description: >-
Streptococcus pyogenes colonizes and infects the upper respiratory tract,
producing acute pharyngitis with fever and systemic inflammatory symptoms.
downstream:
- target: Streptococcal pyrogenic exotoxin response
description: Toxigenic strains can produce superantigenic exotoxins that drive the scarlet fever rash.
- target: Post-streptococcal immune sequelae
description: Untreated or delayed treatment of scarlet fever can permit local and systemic sequelae.
biological_processes:
- preferred_term: response to bacterium
modifier: ABNORMAL
term:
id: GO:0009617
label: response to bacterium
- preferred_term: inflammatory response
modifier: INCREASED
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:37493159
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Group A ß-hemolytic Streptococcus (GABHS) is the leading bacterial cause
of acute pharyngitis in children and adolescents worldwide.
explanation: This supports the upper-airway streptococcal infection node underlying scarlet fever.
- name: Post-streptococcal immune sequelae
description: >-
Scarlet fever can be followed by clinically important local and systemic
sequelae, including acute rheumatic fever, endocarditis, and
glomerulonephritis, which motivates early diagnosis and treatment.
biological_processes:
- preferred_term: immune response
modifier: ABNORMAL
term:
id: GO:0006955
label: immune response
- preferred_term: inflammatory response
modifier: ABNORMAL
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:37062653
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The early diagnosis and treatment of this disease is critical to obviate
the development of local and systemic sequelae such as acute rheumatic
fever, endocarditis, and glomerulonephritis.
explanation: This supports downstream post-streptococcal sequelae as clinically important complications of scarlet fever.
- name: Streptococcal pyrogenic exotoxin response
description: >-
Streptococcal pyrogenic exotoxins act as superantigens and trigger immune
activation, producing the characteristic scarlatiniform rash and mucosal
findings of scarlet fever.
downstream:
- target: Skin rash
description: Toxin-mediated immune activation produces the diffuse erythematous rash.
biological_processes:
- preferred_term: T cell activation
modifier: INCREASED
term:
id: GO:0042110
label: T cell activation
- preferred_term: immune response
modifier: INCREASED
term:
id: GO:0006955
label: immune response
- preferred_term: cytokine-mediated signaling pathway
modifier: INCREASED
term:
id: GO:0019221
label: cytokine-mediated signaling pathway
- preferred_term: biological process involved in interaction with host
modifier: ABNORMAL
term:
id: GO:0051701
label: biological process involved in interaction with host
cell_types:
- preferred_term: T cell
term:
id: CL:0000084
label: T cell
evidence:
- reference: PMID:37062653
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Superantigens (SAgs) secreted by this Group A streptococcus (GAS) usually
overstimulate the human immune system, causing an amplified
hypersensitivity reaction leading to initial symptoms such as sore throat,
high fever, and a sandpaper-like skin rash.
explanation: This directly connects GAS superantigens to immune overactivation and classic scarlet fever symptoms.
- reference: PMID:39370779
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
GAS promotes severe inflammation through mechanisms involving
inflammasomes, IL-1β, and T-cell hyperactivation.
explanation: This supports inflammatory and T-cell activation mechanisms for GAS pathogenicity.
- name: Emergent toxigenic GAS lineages
description: >-
Recent scarlet fever and GAS surveillance has identified changing emm-type
distributions, including emm12, emm1, and M1UK lineages with distinctive
superantigen gene profiles.
downstream:
- target: Streptococcal pyrogenic exotoxin response
description: Toxigenic emm lineages contribute superantigen profiles that feed the toxin-mediated scarlet fever mechanism.
biological_processes:
- preferred_term: biological process involved in interaction with host
modifier: ABNORMAL
term:
id: GO:0051701
label: biological process involved in interaction with host
evidence:
- reference: PMID:40487265
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Sixteen emm types were identified with predominance of emm12 (66.4%) and
emm1 (29.8%).
explanation: This supports emm-type predominance among GAS isolates from children with scarlet fever in Shanghai.
- reference: PMID:40487265
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Four novel M1UK isolates were found in Shanghai, with distinctive
characteristics of presence of speC and ssa.
explanation: This supports emergence of M1UK isolates carrying scarlet-fever-relevant superantigen genes.
phenotypes:
- category: Constitutional
name: Fever
description: Fever is a common systemic manifestation of scarlet fever.
phenotype_term:
preferred_term: Fever
term:
id: HP:0001945
label: Fever
evidence:
- reference: PMID:37062653
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Superantigens (SAgs) secreted by this Group A streptococcus (GAS) usually
overstimulate the human immune system, causing an amplified
hypersensitivity reaction leading to initial symptoms such as sore throat,
high fever, and a sandpaper-like skin rash.
explanation: This supports fever as part of the initial scarlet fever symptom complex.
- category: Head and neck
name: Pharyngitis
description: Scarlet fever commonly occurs with streptococcal pharyngitis.
phenotype_term:
preferred_term: Pharyngitis
term:
id: HP:0025439
label: Pharyngitis
evidence:
- reference: PMID:37493159
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Children with GABHS pharyngitis typically present with an abrupt onset of
fever, intense pain in the throat, pain on swallowing, an inflamed
pharynx, enlarged and erythematous tonsils, a red and swollen uvula,
enlarged tender anterior cervical lymph nodes.
explanation: This supports pharyngitis and sore throat manifestations of GAS disease that underlie scarlet fever.
- category: Dermatologic
name: Skin rash
description: A diffuse erythematous scarlatiniform rash is the defining rash phenotype.
phenotype_term:
preferred_term: Skin rash
term:
id: HP:0000988
label: Skin rash
evidence:
- reference: PMID:37062653
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Superantigens (SAgs) secreted by this Group A streptococcus (GAS) usually
overstimulate the human immune system, causing an amplified
hypersensitivity reaction leading to initial symptoms such as sore throat,
high fever, and a sandpaper-like skin rash.
explanation: This directly supports the rash phenotype and connects it to GAS superantigens.
- category: Dermatologic
name: Finger desquamation
description: Desquamation or peeling can occur after the sandpaper rash of scarlet fever.
phenotype_term:
preferred_term: Finger desquamation
evidence:
- reference: PMID:18801598
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A sandpaper rash over the body with finger desquamation, elevation of
antistreptolysin O and a recent contact with an infected grandson led to
the diagnosis of scarlet fever.
explanation: This case report supports desquamation as part of the scarlet fever clinical presentation.
- category: Head and neck
name: Strawberry tongue
description: Scarlet fever can produce a strawberry tongue appearance.
phenotype_term:
preferred_term: Strawberry tongue
term:
id: HP:0031042
label: Strawberry tongue
evidence:
- reference: PMID:37062653
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
There could be concurrent oral manifestations known as "strawberry tongue"
or "raspberry tongue," which may be first noted by oral health
professionals.
explanation: This supports strawberry tongue as an oral manifestation of scarlet fever.
- category: Head and neck
name: Cervical lymphadenopathy
description: Tender anterior cervical lymph nodes can accompany GAS pharyngitis in scarlet fever.
phenotype_term:
preferred_term: Cervical lymphadenopathy
term:
id: HP:0025289
label: Cervical lymphadenopathy
evidence:
- reference: PMID:37493159
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Children with GABHS pharyngitis typically present with an abrupt onset of
fever, intense pain in the throat, pain on swallowing, an inflamed
pharynx, enlarged and erythematous tonsils, a red and swollen uvula,
enlarged tender anterior cervical lymph nodes.
explanation: This supports anterior cervical lymphadenopathy in the GAS pharyngitis presentation.
diagnosis:
- name: Throat swab microbiologic testing
description: >-
Suspected group A streptococcal pharyngitis associated with scarlet fever is
confirmed with throat swab testing such as culture, rapid antigen testing,
or molecular point-of-care testing.
diagnosis_term:
preferred_term: diagnostic procedure
term:
id: MAXO:0000003
label: diagnostic procedure
results: Detection of group A Streptococcus supports the diagnosis in a compatible clinical syndrome.
evidence:
- reference: PMID:37493159
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Patients suspected of having GABHS pharyngitis should be confirmed by
microbiologic testing (e.g., culture, rapid antigen detection test,
molecular point-of-care test) of a throat swab specimen prior to the
initiation of antimicrobial therapy.
explanation: This supports throat swab microbiologic confirmation before antimicrobial therapy.
- name: Nucleic acid amplification testing for Streptococcus pyogenes
description: >-
NAAT can improve sensitivity for group A Streptococcus detection compared
with rapid antigen testing in pharyngitis evaluation.
diagnosis_term:
preferred_term: diagnostic procedure
term:
id: MAXO:0000003
label: diagnostic procedure
results: NAAT positivity indicates Streptococcus pyogenes detection from a throat swab.
evidence:
- reference: PMID:39518763
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
RADTs showed a sensitivity of 80.76% and a specificity of 100%, while
NAATs demonstrated a sensitivity of 100% and specificity of 96.42%.
explanation: This diagnostic study supports NAAT as a sensitive test for GAS pharyngitis.
treatments:
- name: Beta-lactam antibiotic therapy
description: >-
Penicillin or amoxicillin therapy treats group A streptococcal infection,
reduces symptom duration, and helps prevent immune-mediated complications.
treatment_term:
preferred_term: antimicrobial agent therapy
term:
id: MAXO:0001021
label: antimicrobial agent therapy
therapeutic_agent:
- preferred_term: penicillin
term:
id: CHEBI:17334
label: penicillin
- preferred_term: amoxicillin
term:
id: CHEBI:2676
label: amoxicillin
target_phenotypes:
- preferred_term: Pharyngitis
term:
id: HP:0025439
label: Pharyngitis
- preferred_term: Fever
term:
id: HP:0001945
label: Fever
evidence:
- reference: PMID:37493159
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Antimicrobial therapy should be initiated without delay once the diagnosis
is confirmed. Oral penicillin V and amoxicillin remain the drugs of
choice.
explanation: This supports prompt beta-lactam therapy as first-line management for confirmed GAS pharyngitis/scarlet fever.
- reference: PMID:37062653
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Antibiotics should be prescribed early to mitigate its duration, sequelae,
and community spread.
explanation: This supports early antibiotic treatment to reduce disease duration, complications, and transmission.
- name: Alternative antibiotics for penicillin allergy
description: >-
Cephalosporins can be used for non-anaphylactic penicillin allergy, while
clindamycin and macrolides are alternatives for immediate-type penicillin
hypersensitivity.
treatment_term:
preferred_term: antimicrobial agent therapy
term:
id: MAXO:0001021
label: antimicrobial agent therapy
therapeutic_agent:
- preferred_term: cephalosporin
term:
id: CHEBI:23066
label: cephalosporin
- preferred_term: clindamycin
term:
id: CHEBI:3745
label: clindamycin
target_phenotypes:
- preferred_term: Pharyngitis
term:
id: HP:0025439
label: Pharyngitis
evidence:
- reference: PMID:37493159
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
For patients who have a non-anaphylactic allergy to penicillin, oral
cephalosporin is an acceptable alternative. For patients with a history of
immediate, anaphylactic-type hypersensitivity to penicillin, oral
clindamycin, clarithromycin, and azithromycin are acceptable alternatives.
explanation: This supports cephalosporin and clindamycin-containing alternatives for patients with penicillin allergy.
Scarlet fever is a GAS disease classically characterized by fever, pharyngitis/tonsillopharyngitis, a sandpaper-like erythematous exanthem, and mucosal findings such as “strawberry tongue.” (bergsten2024theintricatepathogenicity pages 2-3, leung2025groupaβhemolytic pages 1-2) The modern resurgence of GAS illnesses after COVID-19 nonpharmaceutical interventions has been linked to changes in circulating GAS lineages and toxin profiles, including expansion of the toxigenic emm1 M1UK lineage with increased SpeA superantigen expression. (rumke2024nationwideupsurgein pages 1-2, rumke2024nationwideupsurgein pages 2-4, bergsten2024theintricatepathogenicity pages 3-4)
Scarlet fever is a clinical syndrome caused by GAS strains producing streptococcal pyrogenic exotoxins/superantigens, presenting with fever and pharyngitis and a diffuse erythematous rash with rough “sandpaper” texture, often accompanied by strawberry tongue and later desquamation. (bergsten2024theintricatepathogenicity pages 2-3, inamadar2018thestrawberrytongue pages 1-2, wu2024epidemiologicalchangesof pages 1-2)
Evidence used here is largely from aggregated disease-level resources (surveillance studies and reviews) plus case reports/series for phenotype details (e.g., oral findings and timing of desquamation). (wu2024epidemiologicalchangesof pages 1-2, slebioda2020scarletfever– pages 3-5, inamadar2018thestrawberrytongue pages 1-2)
Not well characterized in the retrieved sources. Conceptually, immunity accumulates with age; a comprehensive GAS review notes immunity development over time and long-lived antibodies, but protective factors specific to scarlet fever (e.g., correlates of protection) are not quantified here. (bergsten2024theintricatepathogenicity pages 8-10)
A GAS pathogenicity review highlights HLA–superantigen (SpeA) interactions, noting associations of HLA-DQA1/HLA-DQ with increased infection risk and nasal colonization. (bergsten2024theintricatepathogenicity pages 3-4)
Typical timing - Incubation: 2–5 days for GAS pharyngitis. (leung2025groupaβhemolytic pages 1-2) - Rash timing: Often follows pharyngeal symptoms within ~1–2 days (case-based/clinical descriptions). (m.2026araremanifestation pages 1-2) - Desquamation: May occur during convalescence, including palm/sole peeling within ~2 weeks in classic descriptions and case reports. (m.2026araremanifestation pages 1-2, slebioda2020scarletfever– pages 3-5)
Common manifestations - Fever, headache, sore throat, lymphadenopathy, sandpaper-like erythematous rash, and post-rash peeling/desquamation are listed as characteristic clinical features in a large surveillance study. (wu2024epidemiologicalchangesof pages 1-2) - “Strawberry tongue”: a “white strawberry tongue” early with loss of coating in 1–2 days, exposing hypertrophic papillae (red strawberry tongue). (leung2025groupaβhemolytic pages 1-2, inamadar2018thestrawberrytongue pages 1-2) - Pastia lines and circumoral pallor (Filatov mask) are included in clinical descriptions of scarlet fever exanthem variants. (m.2026araremanifestation pages 2-4)
Quality of life / functional impact A contemporary review of GAS pharyngitis reports short-term functional burden: children missed a mean 1.9 days of daycare/school and 42% of parents missed a mean 1.8 workdays. (leung2025groupaβhemolytic pages 6-7)
(These are ontology suggestions; the IDs should be verified against the HPO database.) - Fever — HP:0001945 - Pharyngitis / sore throat — HP:0025421 (pharyngitis) / HP:0033050 (sore throat; verify) - Exanthem / rash — HP:0000988 - Desquamation — HP:0000977 - Strawberry tongue — term exists in HPO (verify exact ID) - Cervical lymphadenopathy — HP:0000450
Not applicable in the Mendelian sense: scarlet fever is not a monogenic inherited disorder.
Evidence indicates host HLA class II variation can modulate susceptibility via SpeA interactions (HLA-DQA1/HLA-DQ). (bergsten2024theintricatepathogenicity pages 3-4)
Not applicable for the human host in typical clinical usage; pathogen regulatory and mobile-element effects exist (prophage-encoded toxins) but were not comprehensively extracted here beyond toxin carriage/expression. (rumke2024nationwideupsurgein pages 2-4, bergsten2024theintricatepathogenicity pages 3-4)
1) Colonization/infection of upper respiratory tract by GAS, with potential asymptomatic carriage in children (~8% school-age carriage cited in a review). (bergsten2024theintricatepathogenicity pages 2-3) 2) Expression and/or increased expression of superantigens/toxins (SpeA, SSA, SpeC), influenced by lineage (e.g., M1UK) and prophage acquisition. (rumke2024nationwideupsurgein pages 2-4, bergsten2024theintricatepathogenicity pages 3-4) 3) Immune activation: superantigen-mediated T-cell hyperactivation through TCR–HLA interactions; clinical immune signatures in acute illness include elevated inflammatory cytokines (IFN-γ, IL-6) alongside regulatory IL-10, with reduced IL-17A reported in one pediatric cohort. (bergsten2024theintricatepathogenicity pages 3-4, keuleyan2025characterizationofstreptococcus pages 1-2) 4) Clinical phenotype: systemic symptoms (fever) and mucocutaneous inflammation resulting in rash and strawberry tongue; later epidermal desquamation/peeling. (wu2024epidemiologicalchangesof pages 1-2, inamadar2018thestrawberrytongue pages 1-2) 5) Downstream immune sequelae risk: GAS infection can be followed by acute rheumatic fever (ARF) and post-streptococcal glomerulonephritis (PSGN) in susceptible settings/populations. (bergsten2024theintricatepathogenicity pages 2-3)
(Verify exact GO IDs against GO.) - T cell activation - Cytokine-mediated signaling pathway - Inflammatory response - Response to bacterium
Chongqing, China (19-year surveillance; publication Sep 2024) - 2005–2023: 9,593 cases; annual average incidence 1.6694 per 100,000; children 3–7 highest burden; kindergarteners 54.32% of cases; male:female incidence ratio 1.51. (wu2024epidemiologicalchangesof pages 1-2) - Predicted 2024–2025 burden: 675 and 705 cases, respectively, using SARIMA. (wu2024epidemiologicalchangesof pages 1-2) - Visual evidence of long-term incidence and 2024–2025 predictions is available in extracted figures. (wu2024epidemiologicalchangesof media b02e46ec, wu2024epidemiologicalchangesof media e239d009)
UK resurgence snapshot (review citing UK surveillance; publication Jun 2023) - Reported “27,486 confirmed scarlet fever cases and 94 deaths from September 2022 to December 2022” (as cited in the review). (matsubara2023recrudescenceofscarlet pages 1-2)
Global burden estimates (review; publication Nov 2024) - Review-level estimates list scarlet fever incidence as 186 per 100,000 children and 33 per 100,000 across all ages. (bergsten2024theintricatepathogenicity pages 2-3)
Scarlet fever is often diagnosed clinically by the combination of pharyngitis/fever and characteristic rash plus oral findings (strawberry tongue), with confirmatory microbiologic testing where appropriate. (leung2025groupaβhemolytic pages 1-2, matsubara2023recrudescenceofscarlet pages 2-4)
Rapid antigen detection test (RADT), NAAT, and culture - Belgium (Nov 2022–Feb 2023; n=82 swabs): RADT sensitivity 80.76% and specificity 100%; NAAT sensitivity 100% and specificity 96.42% vs culture. (panahandeh2024moleculardiagnosticsfor pages 1-2, panahandeh2024moleculardiagnosticsfor pages 2-4)
PCR implementation / operational performance - New Zealand (from Sep 2023; n=1,093 swabs): culture detected 24.0% vs PCR 29.2%; median turnaround time decreased from 44 to 16 hours after introducing PCR. (lucas2024alaboratorydevelopedextraction pages 1-2)
Differentials discussed in clinical case literature include viral exanthems, measles, rubella, Kawasaki disease, infectious mononucleosis, hand-foot-and-mouth disease, and drug eruptions; strawberry tongue is not specific and appears in other toxin-mediated or inflammatory conditions. (slebioda2020scarletfever– pages 3-5, inamadar2018thestrawberrytongue pages 1-2)
Management largely follows GAS pharyngitis treatment principles to eradicate GAS, reduce transmission, and prevent complications. - First-line: Oral penicillin V for 10 days; amoxicillin commonly used in children (e.g., 50 mg/kg/day, max 1200 mg/day) for 10 days. (leung2025groupaβhemolytic pages 6-7) - Contagiousness after therapy: Patients are “usually not contagious 24 hours after initiating appropriate antimicrobial therapy.” (leung2025groupaβhemolytic pages 1-2) - Alternatives (penicillin allergy): Oral cephalosporins for non-anaphylactic allergy; clindamycin/azithromycin/clarithromycin for immediate-type hypersensitivity, with regimen details provided in the review. (leung2025groupaβhemolytic pages 6-7)
(Verify exact MAXO IDs.) - Antibiotic therapy - Penicillin administration - Throat swab diagnostic testing - Patient isolation / infection control
Not addressed in retrieved sources; GAS is described as primarily human-adapted/human-restricted in major reviews, implying limited natural animal disease relevance for scarlet fever per se. (bergsten2024theintricatepathogenicity pages 2-3)
Not systematically extracted in this run (evidence gap). GAS pathogenesis research commonly uses in vitro and animal models, but model details specific to scarlet fever manifestations were not captured in the retrieved evidence.
| Domain (Epidemiology/Resurgence/Transmission/Diagnostics/Treatment) | Setting/Population | Time period | Key quantitative results (incidence, counts, %) | Interpretation/notes | Source (first author year, journal) | URL | Citation context ID |
|---|---|---|---|---|---|---|---|
| Epidemiology | Chongqing, China; reported scarlet fever cases | 2005–2023 | 9,593 cases; annual average incidence 1.6694 per 100,000 | Long-term surveillance shows persistent pediatric burden | Wu 2024, BMC Public Health | https://doi.org/10.1186/s12889-024-20116-5 | (wu2024epidemiologicalchangesof pages 1-2) |
| Epidemiology | Chongqing, China; children 3–7 years | 2005–2023 | Highest average incidence at age 6: 5.0002 per 100,000; kindergarten children 54.32% of cases; students 34.09%; male incidence 1.51× female | Young school/daycare-aged boys were the highest-risk group | Wu 2024, BMC Public Health | https://doi.org/10.1186/s12889-024-20116-5 | (wu2024epidemiologicalchangesof pages 1-2) |
| Epidemiology | Chongqing, China | 2005–2023 | Bimodal seasonal peaks: Apr–Jun and Nov–Dec; incidence increased by 106.54% in 2015–2019 and 39.33% in 2020–2022 vs 2005–2014 | Supports seasonality and post-2011/2015 resurgence pattern | Wu 2024, BMC Public Health | https://doi.org/10.1186/s12889-024-20116-5 | (wu2024epidemiologicalchangesof pages 1-2) |
| Epidemiology | Chongqing, China | 2020–2025 | During zero-COVID period, incidence decreased by 68.61% (2020), 25.66% (2021), and 10.59% (2022) vs predicted; 2023 incidence 1.5168 per 100,000; predicted 675 cases in 2024 and 705 in 2025 | NPIs suppressed transmission; burden expected to rebound | Wu 2024, BMC Public Health | https://doi.org/10.1186/s12889-024-20116-5 | (wu2024epidemiologicalchangesof pages 1-2, wu2024epidemiologicalchangesof media b02e46ec, wu2024epidemiologicalchangesof media e239d009) |
| Epidemiology | Global/summary burden estimates | Contemporary review (published 2024) | Scarlet fever incidence estimated at 186 per 100,000 children and 33 per 100,000 all ages | Review-level estimate; useful for broad burden comparison | Bergsten 2024, Virulence | https://doi.org/10.1080/21505594.2024.2412745 | (bergsten2024theintricatepathogenicity pages 2-3) |
| Resurgence | Shanghai, China; scarlet fever surveillance | 2011–2024 | 25,539 cases; incidence fell from pre-COVID mean 17.1/100,000 (95% CI 9.7–24.3) to post-COVID 4.8/100,000 (95% CI 2.0–10.1); children 4–9 years = 85.6% of cases | No major post-COVID rebound in Shanghai, but substantial ongoing burden in children | Cai 2025, Lancet Regional Health – Western Pacific | https://doi.org/10.1016/j.lanwpc.2025.101576 | (cai2025ongoingepidemicof pages 1-2) |
| Resurgence | Shanghai, China; molecular epidemiology | 2011–2024 | 16 emm types; emm12 66.4%, emm1 29.8%; emm1 ST1274 increased from 10.5% pre-COVID to 73.7% post-COVID; 4 novel M1UK isolates identified | Strain replacement and emergence of M1UK may alter future epidemiology | Cai 2025, Lancet Regional Health – Western Pacific | https://doi.org/10.1016/j.lanwpc.2025.101576 | (cai2025ongoingepidemicof pages 1-2) |
| Resurgence | Netherlands; invasive S. pyogenes isolates | Q1 2022 to Q1 2023 | emm1.0 among invasive isolates rose from 18% (18/100) to 58% (388/670), P<0.0001; M1UK among invasive emm1 rose from 72% to 96% | Strong evidence that recent iGAS surge was driven by expansion of toxigenic M1UK rather than increased carriage | Rümke 2024, Journal of Clinical Microbiology | https://doi.org/10.1128/jcm.00766-24 | (rumke2024nationwideupsurgein pages 1-2, rumke2024nationwideupsurgein pages 2-4) |
| Resurgence | Netherlands; genomic surveillance | 2009–2023 | 2,698 invasive isolates, 351 carriage isolates, WGS of 497 emm1 isolates; DNase Spd1 and SpeC acquired in 9% (46/497) of emm1 isolates | Large-scale molecular surveillance supports increased virulence/fitness of emergent clades | Rümke 2024, Journal of Clinical Microbiology | https://doi.org/10.1128/jcm.00766-24 | (rumke2024nationwideupsurgein pages 1-2) |
| Resurgence | Australia; tertiary hospital GAS isolate collection | 2021–2022 | 17 non-emm1 clinical isolates; 9 emm types; emm22, emm12, emm3 each 18% (3/17); 82% (14/17) carried at least one scarlet-fever–associated superantigen gene | Superantigen carriage was common and not confined to one emm type | Shaw 2024, Pathogens | https://doi.org/10.3390/pathogens13110956 | (shaw2024clinicalsnapshotof pages 1-2) |
| Resurgence | UK surveillance cited in review | Sep–Dec 2022 | 27,486 confirmed scarlet fever cases and 94 deaths; compared with 3,287 infections in the same period of 2017–2018 | Illustrates magnitude of 2022–2023 resurgence in a high-income setting | Matsubara 2023, International Dental Journal | https://doi.org/10.1016/j.identj.2023.03.009 | (matsubara2023recrudescenceofscarlet pages 1-2) |
| Transmission | Household spread of GAS pharyngitis/scarlet fever-related infection | General clinical epidemiology | Approximate household transmission rate 35%; incubation period 2–5 days; usually not contagious 24 h after appropriate antimicrobial therapy | Key operational figures for case management and school exclusion advice | Leung 2025, Current Pediatric Reviews | https://doi.org/10.2174/1573396320666230726145436 | (leung2025groupaβhemolytic pages 1-2) |
| Transmission | Pharyngeal carriage; adults and school-age children | Contemporary review (published 2024) | Asymptomatic carriage ~3% of adults and 8% of school-age children; school outbreaks may involve up to 50% asymptomatic carriage of outbreak strain | Carriage reservoir helps explain classroom spread and difficulty of control | Bergsten 2024, Virulence | https://doi.org/10.1080/21505594.2024.2412745 | (bergsten2024theintricatepathogenicity pages 2-3) |
| Diagnostics | Belgium; 82 throat swabs, culture reference | Nov 2022–Feb 2023 | RADT sensitivity 80.76%, specificity 100%; NAAT sensitivity 100%, specificity 96.42%; 28/82 (34.14%) positive for pathogens, 92.85% of positives were S. pyogenes | NAAT outperformed RADT on sensitivity while maintaining high specificity | Panahandeh 2024, Journal of Clinical Medicine | https://doi.org/10.3390/jcm13216627 | (panahandeh2024moleculardiagnosticsfor pages 1-2, panahandeh2024moleculardiagnosticsfor pages 2-4, panahandeh2024moleculardiagnosticsfor pages 5-7, panahandeh2024moleculardiagnosticsfor pages 4-5) |
| Diagnostics | Belgium; contingency counts | Nov 2022–Feb 2023 | RADT: 21 true positives, 5 false negatives, 0 false positives, 56 true negatives; NAAT: 26 true positives, 0 false negatives, 2 false positives, 54 true negatives | Useful for direct comparison of missed cases by test modality | Panahandeh 2024, Journal of Clinical Medicine | https://doi.org/10.3390/jcm13216627 | (panahandeh2024moleculardiagnosticsfor pages 2-4) |
| Diagnostics | New Zealand; prospective throat swab PCR validation | From 4 Sep 2023; publication 2024 | 1,093 throat swabs; culture positive 262/1,093 (24.0%) vs PCR 319/1,093 (29.2%); overall agreement 94.2%, positive agreement 98.9%, negative agreement 92.8%; median turnaround time improved from 44 h to 16 h | PCR detected more GAS and substantially shortened reporting time | Lucas 2024, New Zealand Medical Journal | https://doi.org/10.26635/6965.6676 | (lucas2024alaboratorydevelopedextraction pages 1-2) |
| Diagnostics | The Gambia; children with pharyngitis | Jun 9, 2021–Sep 26, 2022 | 376 participants; culture positive 37/376 (9.8%); LFT positive 119/376 (31.6%); PCR positive 122/376 (32.4%); ID NOW positive 122/366 (33.3%) | Highlights discordance between molecular tests and culture in a high-carriage setting | Armitage 2025, thesis/report | N/A | (armitage2025epidemiologyofstreptococcus pages 76-78, armitage2025epidemiologyofstreptococcus pages 74-76) |
| Diagnostics | The Gambia; diagnostic accuracy vs culture | Jun 2021–Sep 2022 | LFT sensitivity 83.8%, specificity 74.0%; PCR sensitivity 94.6%, specificity 74.3%; ID NOW sensitivity 94.6%, specificity 73.6% | NAAT/PCR were more sensitive than lateral-flow antigen testing in this cohort | Armitage 2025, thesis/report | N/A | (armitage2025epidemiologyofstreptococcus pages 78-81, armitage2025epidemiologyofstreptococcus pages 76-78) |
| Treatment | GAS pharyngitis/scarlet-fever–relevant management | Contemporary review (published 2025) | Antibiotics started within 48 h shorten recovery by 12–24 h; penicillin V 10 days standard; amoxicillin 50 mg/kg/day (max 1200 mg/day); patients generally noncontagious after 24 h of therapy | Supports current first-line treatment and return-to-school timing | Leung 2025, Current Pediatric Reviews | https://doi.org/10.2174/1573396320666230726145436 | (leung2025groupaβhemolytic pages 6-7, leung2025groupaβhemolytic pages 1-2) |
| Treatment | Comparative antibiotic outcomes | Review evidence | Cephalosporins reduced relapse vs penicillin: children OR 0.55 (95% CI 0.30–0.99), adults OR 0.42 (95% CI 0.20–0.88) | Suggests alternative agents may modestly improve relapse outcomes, though penicillin remains standard first-line therapy | Leung 2025, Current Pediatric Reviews | https://doi.org/10.2174/1573396320666230726145436 | (leung2025groupaβhemolytic pages 7-7) |
| Treatment | Childhood carriage/eradication context | Review evidence | GAS carriage estimated at 5–13% of children; clindamycin for carriage eradication when indicated: 20–30 mg/kg/day, max 900 mg/day, divided TID for 10 days | Routine treatment of carriers is not generally recommended | Leung 2025, Current Pediatric Reviews | https://doi.org/10.2174/1573396320666230726145436 | (leung2025groupaβhemolytic pages 7-7) |
| Epidemiology/Impact | Daycare/school and parent work loss from GAS pharyngitis | Review evidence | Children missed mean 1.9 days of daycare/school; 42% of parents missed mean 1.8 workdays | Indicates nontrivial short-term quality-of-life and economic burden | Leung 2025, Current Pediatric Reviews | https://doi.org/10.2174/1573396320666230726145436 | (leung2025groupaβhemolytic pages 6-7) |
Table: This table summarizes the main quantitative findings extracted from the gathered literature on scarlet fever and related group A streptococcal disease. It highlights recent epidemiology, resurgence patterns, transmission estimates, diagnostic performance, and treatment-related figures useful for a disease knowledge base.
1) PMIDs: Many retrieved sources in this run did not include PMIDs in the extracted metadata; PMIDs should be added during curation by cross-referencing PubMed using the DOI/metadata. 2) Ontology identifiers (MONDO/MeSH/SNOMED/ICD-11): Not retrieved from dedicated ontology resources here; these should be populated from OLS/MONDO/MeSH browser. 3) Protective factors: Not well quantified in the retrieved literature snippets. 4) Model organisms: Not extracted; requires targeted searching in GAS pathogenesis literature.
References
(bergsten2024theintricatepathogenicity pages 2-3): Helena Bergsten and Victor Nizet. The intricate pathogenicity of group a streptococcus : a comprehensive update. Virulence, Nov 2024. URL: https://doi.org/10.1080/21505594.2024.2412745, doi:10.1080/21505594.2024.2412745. This article has 22 citations and is from a peer-reviewed journal.
(leung2025groupaβhemolytic pages 1-2): Alexander K.C. Leung, Joseph M. Lam, Benjamin Barankin, Kin F. Leong, and Kam L. Hon. Group a β-hemolytic streptococcal pharyngitis: an updated review. Current Pediatric Reviews, 21:2-17, Jan 2025. URL: https://doi.org/10.2174/1573396320666230726145436, doi:10.2174/1573396320666230726145436. This article has 14 citations and is from a peer-reviewed journal.
(rumke2024nationwideupsurgein pages 1-2): Lidewij W. Rümke, Matthew A. Davies, Stefan M. T. Vestjens, Boas C. L. van der Putten, Wendy C. M. Bril-Keijzers, Marlies A. van Houten, Nynke Y. Rots, Alienke J. Wijmenga-Monsuur, Arie van der Ende, Brechje de Gier, Bart J. M. Vlaminckx, and Nina M. van Sorge. Nationwide upsurge in invasive disease in the context of longitudinal surveillance of carriage and invasive streptococcus pyogenes 2009–2023, the netherlands: a molecular epidemiological study. Journal of Clinical Microbiology, Oct 2024. URL: https://doi.org/10.1128/jcm.00766-24, doi:10.1128/jcm.00766-24. This article has 38 citations and is from a peer-reviewed journal.
(rumke2024nationwideupsurgein pages 2-4): Lidewij W. Rümke, Matthew A. Davies, Stefan M. T. Vestjens, Boas C. L. van der Putten, Wendy C. M. Bril-Keijzers, Marlies A. van Houten, Nynke Y. Rots, Alienke J. Wijmenga-Monsuur, Arie van der Ende, Brechje de Gier, Bart J. M. Vlaminckx, and Nina M. van Sorge. Nationwide upsurge in invasive disease in the context of longitudinal surveillance of carriage and invasive streptococcus pyogenes 2009–2023, the netherlands: a molecular epidemiological study. Journal of Clinical Microbiology, Oct 2024. URL: https://doi.org/10.1128/jcm.00766-24, doi:10.1128/jcm.00766-24. This article has 38 citations and is from a peer-reviewed journal.
(bergsten2024theintricatepathogenicity pages 3-4): Helena Bergsten and Victor Nizet. The intricate pathogenicity of group a streptococcus : a comprehensive update. Virulence, Nov 2024. URL: https://doi.org/10.1080/21505594.2024.2412745, doi:10.1080/21505594.2024.2412745. This article has 22 citations and is from a peer-reviewed journal.
(inamadar2018thestrawberrytongue pages 1-2): ArunC Inamadar, KeshavmurthyA Adya, and Aparna Palit. The strawberry tongue: what, how and where? Indian Journal of Dermatology, Venereology and Leprology, 84:500-505, Jul 2018. URL: https://doi.org/10.4103/ijdvl.ijdvl_57_17, doi:10.4103/ijdvl.ijdvl_57_17. This article has 28 citations.
(wu2024epidemiologicalchangesof pages 1-2): Rui Wu, Yu Xiong, Ju Wang, Baisong Li, Lin Yang, Han Zhao, Jule Yang, Tao Yin, Jun Sun, Li Qi, Jiang Long, Qin Li, Xiaoni Zhong, Wenge Tang, Yaokai Chen, and Kun Su. Epidemiological changes of scarlet fever before, during and after the covid-19 pandemic in chongqing, china: a 19-year surveillance and prediction study. BMC Public Health, Sep 2024. URL: https://doi.org/10.1186/s12889-024-20116-5, doi:10.1186/s12889-024-20116-5. This article has 9 citations and is from a peer-reviewed journal.
(slebioda2020scarletfever– pages 3-5): Zuzanna Ślebioda, Agnieszka Mania-Końsko, and Barbara Dorocka-Bobkowska. Scarlet fever – a diagnostic challenge for dentists and physicians: a report of 2 cases with diverse symptoms. Dental and Medical Problems, 57:455-459, Dec 2020. URL: https://doi.org/10.17219/dmp/125574, doi:10.17219/dmp/125574. This article has 6 citations and is from a peer-reviewed journal.
(bergsten2024theintricatepathogenicity pages 8-10): Helena Bergsten and Victor Nizet. The intricate pathogenicity of group a streptococcus : a comprehensive update. Virulence, Nov 2024. URL: https://doi.org/10.1080/21505594.2024.2412745, doi:10.1080/21505594.2024.2412745. This article has 22 citations and is from a peer-reviewed journal.
(m.2026araremanifestation pages 1-2): Kavyadeepu R. M. and Mohnish Sekar. A rare manifestation of scarlet fever with a staphylococcal abscess. International Journal of Research in Dermatology, 12:173-177, Feb 2026. URL: https://doi.org/10.18203/issn.2455-4529.intjresdermatol20260378, doi:10.18203/issn.2455-4529.intjresdermatol20260378. This article has 0 citations.
(m.2026araremanifestation pages 2-4): Kavyadeepu R. M. and Mohnish Sekar. A rare manifestation of scarlet fever with a staphylococcal abscess. International Journal of Research in Dermatology, 12:173-177, Feb 2026. URL: https://doi.org/10.18203/issn.2455-4529.intjresdermatol20260378, doi:10.18203/issn.2455-4529.intjresdermatol20260378. This article has 0 citations.
(leung2025groupaβhemolytic pages 6-7): Alexander K.C. Leung, Joseph M. Lam, Benjamin Barankin, Kin F. Leong, and Kam L. Hon. Group a β-hemolytic streptococcal pharyngitis: an updated review. Current Pediatric Reviews, 21:2-17, Jan 2025. URL: https://doi.org/10.2174/1573396320666230726145436, doi:10.2174/1573396320666230726145436. This article has 14 citations and is from a peer-reviewed journal.
(cai2025ongoingepidemicof pages 1-2): Jiehao Cai, Xingyu Zhou, Chi Zhang, Yue Jiang, Panpan Lv, Yibin Zhou, Mingliang Chen, and Mei Zeng. Ongoing epidemic of scarlet fever in shanghai and the emergence of m1uk lineage group a streptococcus: a 14-year surveillance study across the covid-19 pandemic period. The Lancet Regional Health - Western Pacific, 58:101576, May 2025. URL: https://doi.org/10.1016/j.lanwpc.2025.101576, doi:10.1016/j.lanwpc.2025.101576. This article has 13 citations.
(keuleyan2025characterizationofstreptococcus pages 1-2): Emma Keuleyan, Theodor Todorov, Deyan Donchev, Ani Kevorkyan, Radoslava Vazharova, Alexander Kukov, Georgi Todorov, Boriana Georgieva, Iskra Altankova, and Yordanka Uzunova. Characterization of streptococcus pyogenes strains from tonsillopharyngitis and scarlet fever resurgence, 2023—first detection of m1uk in bulgaria. Microorganisms, 13:179, Jan 2025. URL: https://doi.org/10.3390/microorganisms13010179, doi:10.3390/microorganisms13010179. This article has 2 citations.
(wu2024epidemiologicalchangesof media b02e46ec): Rui Wu, Yu Xiong, Ju Wang, Baisong Li, Lin Yang, Han Zhao, Jule Yang, Tao Yin, Jun Sun, Li Qi, Jiang Long, Qin Li, Xiaoni Zhong, Wenge Tang, Yaokai Chen, and Kun Su. Epidemiological changes of scarlet fever before, during and after the covid-19 pandemic in chongqing, china: a 19-year surveillance and prediction study. BMC Public Health, Sep 2024. URL: https://doi.org/10.1186/s12889-024-20116-5, doi:10.1186/s12889-024-20116-5. This article has 9 citations and is from a peer-reviewed journal.
(wu2024epidemiologicalchangesof media e239d009): Rui Wu, Yu Xiong, Ju Wang, Baisong Li, Lin Yang, Han Zhao, Jule Yang, Tao Yin, Jun Sun, Li Qi, Jiang Long, Qin Li, Xiaoni Zhong, Wenge Tang, Yaokai Chen, and Kun Su. Epidemiological changes of scarlet fever before, during and after the covid-19 pandemic in chongqing, china: a 19-year surveillance and prediction study. BMC Public Health, Sep 2024. URL: https://doi.org/10.1186/s12889-024-20116-5, doi:10.1186/s12889-024-20116-5. This article has 9 citations and is from a peer-reviewed journal.
(matsubara2023recrudescenceofscarlet pages 1-2): Victor Haruo Matsubara, Janina Christoforou, and Lakshman Samaranayake. Recrudescence of scarlet fever and its implications for dental professionals. International Dental Journal, 73:331-336, Jun 2023. URL: https://doi.org/10.1016/j.identj.2023.03.009, doi:10.1016/j.identj.2023.03.009. This article has 12 citations and is from a peer-reviewed journal.
(matsubara2023recrudescenceofscarlet pages 2-4): Victor Haruo Matsubara, Janina Christoforou, and Lakshman Samaranayake. Recrudescence of scarlet fever and its implications for dental professionals. International Dental Journal, 73:331-336, Jun 2023. URL: https://doi.org/10.1016/j.identj.2023.03.009, doi:10.1016/j.identj.2023.03.009. This article has 12 citations and is from a peer-reviewed journal.
(panahandeh2024moleculardiagnosticsfor pages 1-2): Mohammad Hossein Panahandeh, Reza Soleimani, Yasmine Nezzar, Hector Rodriguez-Villalobos, Benoît Kabamba-Mukadi, Alexandre Grimmelprez, and Patricia Schatt. Molecular diagnostics for group a streptococcal pharyngitis: clinical and economic benefits in the belgian healthcare context. Journal of Clinical Medicine, 13:6627, Nov 2024. URL: https://doi.org/10.3390/jcm13216627, doi:10.3390/jcm13216627. This article has 1 citations.
(panahandeh2024moleculardiagnosticsfor pages 2-4): Mohammad Hossein Panahandeh, Reza Soleimani, Yasmine Nezzar, Hector Rodriguez-Villalobos, Benoît Kabamba-Mukadi, Alexandre Grimmelprez, and Patricia Schatt. Molecular diagnostics for group a streptococcal pharyngitis: clinical and economic benefits in the belgian healthcare context. Journal of Clinical Medicine, 13:6627, Nov 2024. URL: https://doi.org/10.3390/jcm13216627, doi:10.3390/jcm13216627. This article has 1 citations.
(lucas2024alaboratorydevelopedextraction pages 1-2): Rebecca Lucas, Emma Tapp, Rumbi Chimwayange, Luiza Hermoso, and Matthew Blakiston. A laboratory-developed extraction free real-time pcr for group a streptococcus in throat swabs: greater detection and faster results. The New Zealand medical journal, 137 1607:34-38, Dec 2024. URL: https://doi.org/10.26635/6965.6676, doi:10.26635/6965.6676. This article has 0 citations.
(esposito2025recentchangesin pages 1-2): Susanna Esposito, Marco Masetti, Carolina Calanca, Nicolò Canducci, Sonia Rasmi, Alessandra Fradusco, and Nicola Principi. Recent changes in the epidemiology of group a streptococcus infections: observations and implications. Microorganisms, 13:1871, Aug 2025. URL: https://doi.org/10.3390/microorganisms13081871, doi:10.3390/microorganisms13081871. This article has 6 citations.
(shaw2024clinicalsnapshotof pages 1-2): Phoebe K. Shaw, Andrew J. Hayes, Maree Langton, Angela Berkhout, Keith Grimwood, Mark R. Davies, Mark J. Walker, and Stephan Brouwer. Clinical snapshot of group a streptococcal isolates from an australian tertiary hospital. Pathogens, 13:956, Nov 2024. URL: https://doi.org/10.3390/pathogens13110956, doi:10.3390/pathogens13110956. This article has 1 citations.
(panahandeh2024moleculardiagnosticsfor pages 5-7): Mohammad Hossein Panahandeh, Reza Soleimani, Yasmine Nezzar, Hector Rodriguez-Villalobos, Benoît Kabamba-Mukadi, Alexandre Grimmelprez, and Patricia Schatt. Molecular diagnostics for group a streptococcal pharyngitis: clinical and economic benefits in the belgian healthcare context. Journal of Clinical Medicine, 13:6627, Nov 2024. URL: https://doi.org/10.3390/jcm13216627, doi:10.3390/jcm13216627. This article has 1 citations.
(panahandeh2024moleculardiagnosticsfor pages 4-5): Mohammad Hossein Panahandeh, Reza Soleimani, Yasmine Nezzar, Hector Rodriguez-Villalobos, Benoît Kabamba-Mukadi, Alexandre Grimmelprez, and Patricia Schatt. Molecular diagnostics for group a streptococcal pharyngitis: clinical and economic benefits in the belgian healthcare context. Journal of Clinical Medicine, 13:6627, Nov 2024. URL: https://doi.org/10.3390/jcm13216627, doi:10.3390/jcm13216627. This article has 1 citations.
(armitage2025epidemiologyofstreptococcus pages 76-78): EP Armitage. Epidemiology of streptococcus pyogenes in the gambia: investigating carriage and disease burden, transmission dynamics and diagnostic accuracy. Unknown journal, 2025.
(armitage2025epidemiologyofstreptococcus pages 74-76): EP Armitage. Epidemiology of streptococcus pyogenes in the gambia: investigating carriage and disease burden, transmission dynamics and diagnostic accuracy. Unknown journal, 2025.
(armitage2025epidemiologyofstreptococcus pages 78-81): EP Armitage. Epidemiology of streptococcus pyogenes in the gambia: investigating carriage and disease burden, transmission dynamics and diagnostic accuracy. Unknown journal, 2025.
(leung2025groupaβhemolytic pages 7-7): Alexander K.C. Leung, Joseph M. Lam, Benjamin Barankin, Kin F. Leong, and Kam L. Hon. Group a β-hemolytic streptococcal pharyngitis: an updated review. Current Pediatric Reviews, 21:2-17, Jan 2025. URL: https://doi.org/10.2174/1573396320666230726145436, doi:10.2174/1573396320666230726145436. This article has 14 citations and is from a peer-reviewed journal.